Lutein and zeaxanthin are carotenoids that concentrate specifically in the macula of the eye, forming macular pigment that filters blue light and protects against oxidative damage. The landmark AREDS2 trial (4,203 participants) confirmed that 10mg lutein + 2mg zeaxanthin daily reduced progression to advanced AMD by 10-25% over 5 years. Our research identifies this as one of the most evidence-backed supplement applications in existence — the FDA even authorized a qualified health claim. The emerging cognitive benefits (brain lutein concentration correlates with cognitive function) add a second compelling application.
Lutein and zeaxanthin are the ONLY carotenoids that accumulate in the macula — they're actively transported there by specific binding proteins (StARD3 for lutein, GSTP1 for zeaxanthin). Once in the macula, they serve two functions: (1) absorbing blue light (400-500nm) before it reaches photoreceptors — acting as internal sunglasses — and (2) quenching reactive oxygen species generated by light exposure. The macula has the highest metabolic rate per gram of any tissue in the body, making it exceptionally vulnerable to oxidative damage. Lutein also accumulates in the brain, where it comprises 60-70% of total brain carotenoids despite being only 12% of circulating carotenoids, suggesting active preferential uptake.
No significant drug interactions have been identified in clinical literature. Lutein and zeaxanthin are naturally occurring dietary carotenoids with no known pharmacological interactions. They may compete with beta-carotene for absorption (hence the AREDS2 switch from beta-carotene to lutein).
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.